Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Table 3 Incidence of neuropathy in statin + metformin user and non-user group

				Propensity score-matched1
	Statin + metformin user, n (%)	Non-user, n (%)	P value	Statin + metformin user, n (%)	Non-user, n (%)	P value
2016
Neuropathy incidence	438/14524 (3.02)	83/2175 (3.82)	0.0452	71/2175 (3.26)	83/2175 (3.82)	0.3248
2017
Neuropathy incidence	472/16096 (2.93)	65/2040 (3.19)	0.5239	62/2040 (3.04)	65/2040 (3.19)	0.7868

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).